Lullabies for epilepsy: a musical stress relief for expectant moms
NCT ID NCT05503290
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests whether participating in the Lullaby Project—where pregnant women with epilepsy work with musicians to create a personal lullaby—can improve their quality of life and reduce anxiety, depression, and stress. Thirty first-time pregnant women with epilepsy will be randomly assigned to the lullaby program or standard care. The goal is to see if this creative, non-drug approach offers emotional benefits during pregnancy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Lullaby Project (music composition program)
- What this could lead to
- If it works, this could offer a simple, non-drug way to ease stress and improve well-being during pregnancy for people with epilepsy.
- What could go wrong
- This is a very small pilot study (30 people) with no blinding, so results may not be generalizable. The main benefit is likely emotional support, not a medical treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2023
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * at least 18 years of age * currently pregnant and primiparous * able to provide informed consent * able to have internet access * have a confirmed diagnosis of epilepsy based on EEG or clinical evidence Exclusion Criteria: * need of a language interpreter to provide informed consent and/or communicate with the MH-RTH musician * prior involvement in the Lullaby Project
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Epilepsy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Health Network
RECRUITINGToronto, Ontario, M5T 2S8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can lavender and lullabies help kids with epilepsy sleep better?
- Reading the Brain's signals to predict who benefits from deep brain stimulation
- Can a Comfort-Focused education program improve life with epilepsy?
- Can video games rewire young brains after injury?
- High-Fat Diet's effect on epilepsy: scientists track brain signals
- Epilepsy drug candidate put to the test in healthy volunteers